Galmed Pharmaceuticals


Galmed Dips 2% On Larger-Than-Expected Quarterly Loss

Galmed Pharmaceuticals declined 2% to close at $3.42 on March 18 after the clinical-stage biopharmaceutical company posted a wider-than-feared loss in the fourth …

Galmed Pharmaceuticals (GLMD): Next Stop, $30?

It’s a big day for Galmed Pharmaceuticals (NASDAQ:GLMD). The drug maker released positive phase Phase 2b data for Aramchol in NASH that had many, even …

Why Galmed Pharmaceuticals (GLMD) Shares Skyrocketed Over 200% Today

Investors love biotech stocks for the lottery ticket-like returns they can offer if a company strikes medical gold. Case in point: Galmed Pharmaceuticals …

Maxim Assigns Buy On Galmed Pharmaceuticals Following The Award Of Fast Track Designation

In a research note issued today, Maxim Group analyst Jason Kolbert assigned a Buy rating on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) with a $24 price target, …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts